Methamphetamine (MA) use and MA-induced psychosis are associated with increasing aberrations in the compensatory immunoregulatory system, interleukin-1α, and CCL5 levels.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
received:
30
05
2023
accepted:
31
10
2023
revised:
24
10
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
epublish
Résumé
There are only a few studies reporting on the immunological profiles of methamphetamine (MA) use, MA dependency, or MA-induced psychosis (MAP). This study measured M1 macrophage, T helper (Th)-1, Th-2, growth factor, and chemokine profiles, as well as the immune inflammatory response system (IRS) and compensatory immunoregulatory system (CIRS) in peripheral blood samples from patients with MA use (n = 51), MA dependence (n = 47), and MAP (n = 43) in comparison with controls (n = 32). We discovered that persistent MA use had a robust immunosuppressive impact on all immunological profiles. The most reliable biomarker profile of MA use is the combination of substantial CIRS suppression and a rise in selected pro-inflammatory cytokines, namely CCL27 (CTACK), CCL11 (eotaxin), and interleukin (IL)-1α. In addition, MA dependency is associated with increased immunosuppression, as demonstrated by lower stem cell factor levels and higher IL-10 levels. MAP is related to a significant decrease in all immunological profiles, particularly CIRS, and an increase in CCL5 (RANTES), IL-1α, and IL-12p70 signaling. In conclusion, long-term MA use and dependency severely undermine immune homeostasis, whereas MAP may be the consequence of increased IL-1α - CCL5 signaling superimposed on strongly depleted CIRS and Th-1 functions. The widespread immunosuppression established in longstanding MA use may increase the likelihood of infectious and immune illness or exacerbate disorders such as hepatitis and AIDS. Furthermore, elevated levels of CCL5, CCL11, CCL27, IL-1α, and/or IL-12p70 may play a role in the peripheral (atherosclerosis, cutaneous inflammation, immune aberrations, hypospermatogenesis) and central (neuroinflammation, neurotoxic, neurodegenerative, depression, anxiety, and psychosis) side effects of MA use.
Identifiants
pubmed: 37996407
doi: 10.1038/s41398-023-02645-6
pii: 10.1038/s41398-023-02645-6
pmc: PMC10667231
doi:
Substances chimiques
Interleukin-1alpha
0
Cytokines
0
Biomarkers
0
Intercellular Signaling Peptides and Proteins
0
CCL5 protein, human
0
Chemokine CCL5
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361Subventions
Organisme : Faculty of Medicine, Chulalongkorn University
ID : FF66
Organisme : Faculty of Medicine, Chulalongkorn University
ID : Sompoch Endowment Fund
Organisme : Faculty of Medicine, Chulalongkorn University
ID : Centre for Addiction Studies
Organisme : Thai Health Promotion Foundation (ThaiHealth)
ID : 66-00111
Informations de copyright
© 2023. The Author(s).
Références
Cells. 2022 May 07;11(9):
pubmed: 35563878
PLoS One. 2012;7(12):e49897
pubmed: 23227154
Mult Scler. 2016 Oct;22(11):1405-1412
pubmed: 26733422
Addict Behav. 2011 Jan-Feb;36(1-2):156-60
pubmed: 20888699
Hum Psychopharmacol. 2019 Sep;34(5):e2710
pubmed: 31441135
Eur J Pharmacol. 2008 Sep 11;592(1-3):93-5
pubmed: 18656466
Neurotox Res. 2011 Jul;20(1):59-68
pubmed: 20953917
Nat Med. 2012 Dec;18(12):1812-9
pubmed: 23178247
Addiction. 2009 Jul;104(7):1085-99
pubmed: 19426289
Mol Neurobiol. 2020 Feb;57(2):778-797
pubmed: 31473906
Psychoneuroendocrinology. 2018 Nov;97:37-46
pubmed: 30005280
Front Neurosci. 2015 Jan 12;8:445
pubmed: 25628526
J Neuroinflammation. 2017 Mar 9;14(1):49
pubmed: 28279172
Neurosci Lett. 1993 Nov 26;163(1):41-4
pubmed: 8295729
Drug Alcohol Rev. 2010 Jul;29(4):456-61
pubmed: 20636664
Pharmacol Res. 2017 Jun;120:60-67
pubmed: 28302577
Front Psychiatry. 2015 Dec 18;6:178
pubmed: 26732994
J Immunol. 2010 Sep 1;185(5):2867-76
pubmed: 20668216
J Leukoc Biol. 2016 Jan;99(1):213-23
pubmed: 26302754
Neuromolecular Med. 2002;2(1):71-85
pubmed: 12230306
Mol Med. 1995 Sep;1(6):690-9
pubmed: 8529135
Immunopharmacol Immunotoxicol. 2002 May;24(2):187-97
pubmed: 12066846
Addiction. 2006 Oct;101(10):1473-8
pubmed: 16968349
JAMA Psychiatry. 2020 Sep 1;77(9):959-966
pubmed: 32267484
PLoS One. 2012;7(2):e31031
pubmed: 22359561
Neurosci Lett. 2012 Sep 6;525(1):23-8
pubmed: 22871478
J Neurochem. 2002 Sep;82(6):1311-29
pubmed: 12354279
Biol Psychiatry. 2009 Mar 15;65(6):481-8
pubmed: 19058794
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5
pubmed: 10588729
Addict Biol. 2023 Oct;28(10):e13333
pubmed: 37753569
Subst Use Misuse. 2019;54(4):549-559
pubmed: 30693832
Eur Neuropsychopharmacol. 2019 Mar;29(3):416-431
pubmed: 30594344
Subst Abuse Treat Prev Policy. 2009 Jul 21;4:16
pubmed: 19622171
ACS Omega. 2022 Feb 05;7(6):5190-5196
pubmed: 35187334
Int Immunopharmacol. 2002 Jun;2(7):951-62
pubmed: 12188036
PLoS Pathog. 2008 Feb 8;4(2):e28
pubmed: 18282092
Acta Psychiatr Scand. 1994 May;89(5):346-51
pubmed: 8067274
BMC Psychiatry. 2022 May 31;22(1):369
pubmed: 35641947
Int Immunopharmacol. 2005 Mar;5(3):609-18
pubmed: 15683856
Mol Immunol. 2020 May;121:159-166
pubmed: 32222586
Immunobiology. 2013 Aug;218(8):1063-8
pubmed: 23518444
J Pharmacol Exp Ther. 1991 Dec;259(3):988-96
pubmed: 1762091
Cell Death Discov. 2018 Mar 19;4:44
pubmed: 29581895
Scand J Immunol. 1998 Nov;48(5):502-8
pubmed: 9822259
Neurochem Res. 2022 Apr;47(4):872-884
pubmed: 34982394
Neurosci Biobehav Rev. 2021 Jan;120:537-541
pubmed: 33031817
Medicine (Baltimore). 2018 Aug;97(34):e11905
pubmed: 30142795
Cells. 2022 Nov 21;11(22):
pubmed: 36429122
Front Psychiatry. 2020 Dec 11;11:594766
pubmed: 33362607
Brain Res Brain Res Rev. 2001 Aug;36(1):1-22
pubmed: 11516769
Neuropsychopharmacology. 2013 Sep;38(10):1864-70
pubmed: 23594818
Acta Neuropsychiatr. 2023 Jun;35(3):123-137
pubmed: 36373497
J Toxicol Environ Health A. 2005 Dec 10;68(23-24):2133-45
pubmed: 16326429
Psychiatry Res. 2000 Nov 20;96(3):245-53
pubmed: 11084220
Int Immunopharmacol. 2017 Aug;49:77-84
pubmed: 28551495
J Pharmacol Exp Ther. 2023 Jan;384(1):205-223
pubmed: 36310035
Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65
pubmed: 19579286
Curr Neuropharmacol. 2017;15(5):762-770
pubmed: 27855594
BMC Immunol. 2016 Apr 23;17(1):7
pubmed: 27107567
Expert Opin Ther Targets. 2012 Nov;16(11):1097-112
pubmed: 22925041
IUBMB Life. 2015 May;67(5):323-30
pubmed: 25906979
Cells. 2021 Oct 28;10(11):
pubmed: 34831151
Addiction. 2014 Jun;109(6):965-76
pubmed: 24521142
J Neuroimmunol. 2000 Nov 1;111(1-2):109-21
pubmed: 11063828
Mol Neurobiol. 2018 Dec;55(12):8885-8903
pubmed: 29611101
J Infect Dis. 2009 Jul 1;200(1):131-41
pubmed: 19473099
Brain Behav Immun. 2016 Jan;51:99-108
pubmed: 26254235